Systemic Lupus Erythematosus

The Lupus Research Alliance's 2022 Global Team Science Awards (GTSA) grant will provide $3 million for 3 years to each of the winners.

"The high prevalence of severe infection in newly diagnosed SLE implies that infections may be related to the underlying immune disturbance of SLE itself.”

An observational cross-sectional study finds that patients suffering from such inflammatory conditions had a higher average number of missing teeth compared to the control group.

Although a third dose of mRNA vaccine significantly increased antireceptor-binding domain (RBD) titer in a previous study, clinical factors associated with the immunogenicity in immunosuppressed populations have not been adequately studied.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 23, 2022.

25% of patients presented with extensive blood-brain barrier leakage, which was linked to both cognitive impairment and shorter disease duration.

Previous assessments of the prevalence of lupus were conducted in short periods of time, therefore limiting the insight into long-term trends and potential explanations for the observed patterns.

As treatment options expand in SLE with an increasing number of targeted therapeutics, we can be optimistic about the potential to improve disease outcomes.

Additional doses improved seroconversion and most vaccinated patients with lupus experienced a generally mild course of the disease.

Iwasaki and her team analyzed 3220 unique sequences of endogenous retroviruses that are a part of the human genetic make up or genome to understand if retroviruses cause or worsen this disease.

SLE-dysregulated genes were linked to biological functions and gene networks, including regulation of type I interferon-mediated signaling pathway, response to steroid hormone, and response to hypoxia.

The complete ACR manuscript is available to elaborate on the earlier summary of antirheumatic medication for patients who are undergoing total hip or total knee anthroplasty.

Data from an analysis of the National Inpatient Sample provides insight into the risk of pregnancy complications among women with systemic lupus erythematosus compared to their counterparts without systemic lupus erythematosus in the US over a decade-long period.

Albert Roy, of Lupus Therapeutics, comments on the recent phase 2 trial data that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Massimo Radin, MD, PhD, discusses how low complement levels in the first trimester can predict disease flare in pregnant patients with systemic lupus erythematosus.

Bristol Myers Squibb announced positive results from a phase 2 trial that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 7, 2022.

The cross-sectional analysis determined cognitive performance of patients with systemic lupus erythematosus was significantly lower when compared with controls in both motor speed and psychomotor speed domains.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 30, 2022.

Manuel Francisco Ugarte-Gil, MD, MSc, explains the impact that severe flares have on health-related quality of life for patients with systemic lupus erythematosus.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2022.

Shanthini Kasturi, MD, MS, discusses the importance of patient-reported outcome measures to optimize the care of patients with systemic lupus erythematosus.

Joyce C. Chang MD, MSCE, discusses the racial disparities in renal outcomes for hospitalized children with systemic lupus erythematosus.